Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab plus physician's choice chemotherapy versus trastuzumab plus physician's choice chemotherapy in metastatic HER2-positive breast cancer after trastuzumab deruxtecan
jRCT2031240407Phase 3Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
A Phase 3 trial of zanidatamab, trastuzumab, eribulin, gemcitabine, vinorelbine in breast cancer, sponsored by Jazz Pharmaceuticals plc. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031240407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240407.